ProCE Banner Activity

Phase II ELARA: Extended Follow-up and Subgroup Analysis of Tisagenlecleucel in High-Risk R/R Follicular Lymphoma

Slideset Download
Conference Coverage
Tisagenlecleucel demonstrated high response rate and durability in patients with high-risk R/R FL, including POD24 and high TMTV though reduced in comparison to low-risk disease.

Released: December 13, 2021

Expiration: December 12, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation